In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
The economics and global implications of the French Google decision in ad tech
In this new episode of Antitrust Code by Concurrences, Mikaël Hervé explains the economics and global implications of the French Google decision in ad...